Pharma BD Deal Intelligence
Outcome grade pending — assessed 5 years post-close.
Full analysis, sources & comparables →Charles River Laboratories has agreed to acquire cell and gene therapy CDMO Cognate BioServices for $875 million. The deal coincides with broader CDMO arms…
Novasep is divesting its Henogen viral vector business to Thermo Fisher for EUR 725 million ($875 million) and will retain its small-molecule API contract…
At year-end 2021, there were 2,329 ongoing regenerative medicine and advanced therapy clinical trials globally, including 1,490 cell-based, 466 gene therapy…
Source summaries from our enrichment pipeline; follow links for originals.
All 11 sources with sentiment breakdown →
Thermo Fisher Scientific agreed to acquire Henogen S.A., Novasep's viral vector manufacturing business in Belgium, for approximately EUR 725M (~$875M) cash. The acquisition expanded Thermo Fisher's gene therapy CDMO capabilities.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Thermo Fisher Scientific Inc. / Henogen S.A. (Novasep viral vector business) (this deal) | 2021 | $875M | — |
| Thermo Fisher Scientific Inc. / Patheon N.V. | 2017 | $7.2B | 89 |
| Thermo Fisher Scientific Inc. / Life Technologies Corporation | 2013 | $15.1B | 84 |
| Thermo Fisher Scientific Inc. / PPD Inc. | 2021 | $17.4B | 77 |
| Thermo Fisher Scientific Inc. / Dionex Corporation | 2010 | $2.1B | 76 |
| Thermo Fisher Scientific Inc. / Brammer Bio | 2019 | $1.7B | — |
| Thermo Fisher Scientific Inc. / Clario Holdings, Inc. | 2025 | $9.4B | — |
← Browse all deals · How we score deals
More: 2021 deals · Thermo Fisher Scientific Inc. deals · Gene Therapy deals